NASDAQ$ABSI
Absci Corp · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Absci reported its financial results for the fourth quarter and year ended December 31, 2023.
Absci reported Q4 2023 revenue of $0.3 million and a net loss of $23.5 million. The company highlighted its progress in AI-driven biologic drug discovery, including the initiation of IND-enabling studies for ABS-101 and a new collaboration with AstraZeneca.
- Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody.
- Entered into a collaboration with AstraZeneca for up to $247M in deal value, plus royalties.
- Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering.
- Presented positive preclinical data for ABS-101, which exhibited properties consistent with a potentially superior product profile.
Headline financials
Revenue & EPS history
Absci · Revenue · Quarterly
$338K
Forward guidance
Absci anticipates signing additional drug creation partnerships with at least four Partners in 2024, including one or more multi-program partnerships. Absci expects a gross use of cash, cash equivalents, and short-term investments of approximately $80 million for the fiscal year ending December 31, 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-9.1%
Avg return
Earnings day
-9.1%
Avg return
5 days after
-9.3%
Avg return
30 days after
21%
5 / 24 earnings
Positive
+13.8%
Q2 2022
Best reaction
-28.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -5.6% | +8.6% | — | |
| Q1 2026 | -3.4% | -10.1% | +7.1% | |
| Q3 2025 | -22.4% | -16.5% | +7.1% | |
| Q2 2025 | +5.1% | -4.7% | -14.1% | |
| Q1 2025 | -0.7% | -6.4% | -6.1% | |
| Q4 2024 | -3.2% | +0.6% | +0.3% | |
| Q3 2024 | -26.6% | -33.6% | -14.0% | |
| Q2 2024 | +6.7% | +7.5% | +0.5% | |
| Q1 2024 | -4.5% | -8.8% | -13.6% | |
| Q4 2023 | -2.8% | +2.4% | -6.3% | |
| Q3 2023 | +12.0% | +16.0% | +120.8% | |
| Q2 2023 | -2.4% | +0.0% | -1.2% | |
| Q1 2023 | -6.4% | +11.2% | +34.4% | |
| Q4 2022 | -0.8% | -0.3% | -25.2% | |
| Q3 2022 | -0.3% | +1.6% | -14.7% | |
| Q2 2022 | +13.8% | +9.0% | -1.4% | |
| Q1 2022 | -11.3% | -9.0% | -21.7% | |
| Q4 2021 | +7.2% | +9.6% | +3.8% | |
| Q3 2021 | -28.5% | -38.0% | -41.4% | |
| Q3 2020 | -28.5% | -38.0% | -41.4% | |
| Q1 2021 | -28.9% | -30.1% | -46.4% | |
| Q2 2021 | -28.9% | -30.1% | -46.4% | |
| Q2 2020 | -28.9% | -30.1% | -46.4% | |
| Q4 2020 | -28.9% | -30.1% | -46.4% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro